A Study of MK0364 in Obese Patients (0364-014)

A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of Taranabant (MK0364) in Obese Patients Followed by a 1-Year Extension

A worldwide study in obese patients to assess the efficacy, safety, and tolerability of an investigational drug.

Inclusion Criteria:

• Body Mass Index (BMI) between 30-43 kg/m2

Exclusion Criteria:

• History of major psychiatric disorder
• History of seizures or at high risk of developing seizures
• Blood pressure greater than 160/100
• Fasting blood glucose greater than 126 mg/dL
• Triglycerides greater than 600 mg/dL